

QUERCETIN, MADE BETTER

 **indena**[®]

INDUSTRIA

DERIVATI

NATURALI

HEALTH - FOOD

QUERCEFIT[®]

QUERCETIN PHYTOSOME[®]

QUERCEFIT[®]

Please note this documentation is available for various countries all over the world and hence it may contain statements or product classification not applicable to your country. The claims made are in reference to ingredients only, hence they do not refer to finished products and they may not comply with Regulation EC n. 1924/2006. The marketer of any finished product containing any ingredient is responsible for assuring that the destination of the product and the claims made for the finished product are lawful and comply with all applicable laws and regulations of the country or countries in which the product is to be sold.

WHAT IS QUERCEFIT®?

QUERCEFIT® is the patent pending¹ food grade delivery system of **quercetin** from *Sophora japonica* L., formulated with Phytosome® proprietary technology to **optimize the biological absorption of the flavonoids**, supporting the overall wellbeing in many conditions. Compared to the unformulated quercetin, **bioabsorption and solubility are greatly optimized** so it can be used at lower dosages retaining its efficacy.²

IMMUNITY HEALTH AND SENOLYTIC FUNCTION

Recent studies^{3,4} show that **QUERCEFIT®** helps maintaining immune system health and modulates cytokines cascade, thus **improving the conditions of those exposed to Covid-19, precisely thanks to its senolytic function**: the product supplementation **helps the health condition of people in the initial phases of SARS-CoV-2, without substituting the standard treatments envisaged by the medical protocols**. In fact, the severity of illness often depends by the way the initial phases are faced.

THE NATURAL REMEDY IN THE ALLERGY ERA

In a first controlled **human study on discomforts during allergy season, after 30 days of supplementation with QUERCEFIT®** plus the standard management (SM) versus the SM alone, it has been demonstrated:⁵

- up to **50% reduction of day intermittent discomforts frequency**
- up to **70% reduction of night intermittent discomforts frequency**
- **maintenance of breath function** (Peak Expiratory Flow) **at physiological levels in mild-persistent discomforts**

In a second controlled **human study focussing on local skin discomforts, QUERCEFIT® was administrated for just 3 days**, then followed by a local histamine skin stimulus.

Compared to the control, only the **healthy volunteers administered with the extract** showed statistically significant:⁶

- **dose-dependent control of all main local conditions;**
- **skin conditions amelioration and capillary filtration reduction**

S P E C I F I C A T I O N S

- **34-42% quercetin** by HPLC • suggested dose: **250 mg once or twice a day**
- **yellow powder** for use in nutritional supplements
- **compliant** with main **worldwide markets food regulations** (BELFRIT, US, EU)
- **high tolerability** in individuals assuming **antiplatelet agents, anticoagulants or living with diabetes**.⁷

BETTER **PERFORMANCE**, FASTER **RECOVERY**

In a **controlled human study**⁸ on healthy triathlon athletes, **QUERCEFIT®** demonstrated to **support optimal physical performance** and **prompt recovery**:

- statistically significant **results in each single triathlon test** (swimming, biking, running);
- **higher triathlon time reduction (-11.3%)** compared to control (-3.9%) **after just 14 days of oral supplementation**;
- **reduced discomfort** related to sport activity;
- **lower oxidative stress (PFR) 1 hr after the final run** (Higher levels of PFR found in control have been associated to a delayed recovery time from fatigue);
- **healthy blood levels maintenance**, with a **reduced UBR** (Unconjugated Bilirubin) **and LDH** (Lactate Dehydrogenase), after prolonged sport activity.

References

- ¹ International patent application number PCT EP2018/054533 filed on 23/02/2018.
- ² Riva A. *et al.*, *Eur J Drug Metab Pharmacokinet.* 2018 Oct 16. doi: 10.1007/s13318-018-0517-3.
- ³ Di Pierro *et al.*, *International Journal of General Medicine* 2021:14 2359-2366.
- ⁴ Di Pierro *et al.*, *International Journal of General Medicine* 2021:14 2807-2816.
- ⁵ Cesarone, M. R., *et al.*, *Minerva medica* [2019].
- ⁶ Riva A. *et al.*, *Minerva Cardioangiol.* 2018 Sep 13. doi: 10.23736/S0026-4725.18.04795-3.
- ⁷ Manuscript submitted.
- ⁸ Riva A. *et al.*, *Minerva Medica* 2018 august;109(4):285-9.



HEADQUARTERS - INDENA S.p.A.

Viale Ortles, 12
20139 Milan - Italy
tel. +39 02 574961

INDENA BIOTECHNOLOGY (Shanghai) Co., Ltd.

Unit 810, Plaza 336, No.336 Middle XiZang Road
Shanghai 200001- China
tel. +86 21 2281 5900

INDENA Brasil Ltda

Rua Bandeira Paulista, 600
CEP 04532-001
São Paulo - Brazil
tel. +55 1 127 690 624

INDENA JAPAN Co., Ltd.

KDDI Bld. 21F. 1-8-1 Otemachi
Chyoda-Ku Tokyo 100-0004 - Japan
tel. +81 3 3243 9924

INDENA S.A.S.

7, Rue Lamennais
75008 Paris - France
tel. +33 1 45229128

INDENA USA Inc.

Two Union Square
601 Union Street, Suite 330
Seattle, WA 98101 - USA
tel. +1 206 340 6140

indena.com

